Corbus Pharmaceuticals Welcomes Rachelle Jacques as New Board Chair

Corbus Pharmaceuticals Welcomes Rachelle Jacques as New Board Chair

Norwood, Massachusetts — Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a prominent clinical-stage biopharmaceutical company dedicated to tackling oncology and obesity, has appointed Rachelle Jacques as Chair of its Board of Directors. This change became effective on May 15, marking a significant shift in leadership as she takes the reins from the founding Chair, Alan Holmer, who will continue to serve on the Board.

Yuval Cohen, Ph.D., the Chief Executive Officer of Corbus, expressed gratitude towards Alan Holmer for his over ten years of dedicated leadership. "Rachelle is a seasoned biopharmaceutical executive, and her innovative and strategic thinking has been invaluable to us as a Board member. We anticipate her vision and leadership as we embark on an exciting new chapter, with pivotal clinical readouts from our pipeline expected soon," he stated.

Rachelle Jacques: Experience and Vision

Rachelle Jacques shared her enthusiasm about stepping into the Chair role at a critical time for Corbus. "I feel privileged to take on this responsibility as we push our diverse pipeline towards significant milestones this year," she remarked. Jacques highlighted the company’s targeted oncology programs, CRB-701 and CRB-601, which aim to combat aggressive cancers. Additionally, she noted their obesity program, designed to address a pressing public health challenge, as a driving force for her motivation.

Reflecting on his tenure, Alan Holmer remarked, "Serving as Chair has been both an honor and privilege. We are clearly on a positive and exciting trajectory. Rachelle's extensive background in both big pharma and biotech will be crucial as we navigate this transition smoothly together." Jacques’ years of service on Corbus' Board and her contributions to various committees have led to this significant advancement in her career.

Jacques’ Background and Achievements

With over 25 years of experience in leadership, Rachelle Jacques has a proven track record of driving transformative therapies through various roles, including CEO and other high-ranking executive positions. She has been instrumental in advancing key initiatives at Corbus Pharmaceuticals and has previously served on the board of directors of uniQure N.V. (Nasdaq: QURE), accelerating gene therapies for genetic diseases. Her leadership journey included being the CEO of Akari Therapeutics Plc (Nasdaq: AKTX), where she developed treatments for autoimmune and inflammatory diseases.

Jacques has also held notable roles such as senior vice president at Alexion Pharmaceuticals, where she directed global commercialization strategies across multiple therapeutic areas. Her early career featured positions at Baxter, encompassing business operations and finance, and she has extensive international experience from her time at Dow Corning, managing operations across several continents.

Corbus’ Commitment to Innovation

Corbus Pharmaceuticals is committed to innovating solutions to tackle serious health challenges. The company’s therapeutic pipeline includes CRB-701, an advanced antibody-drug conjugate targeting cancer cells; CRB-601, an anti-integrin monoclonal antibody aimed at inhibiting TGF? activation; and CRB-913, which acts as a CB1 receptor inverse agonist designed for obesity treatment. This ambitious pipeline reflects the company's resolve in addressing critical health care issues.

As Corbus progresses, its headquarters located in Norwood remains the hub for navigating these advancements. The company is dedicated to exploring and developing scientifically-backed therapies that not only meet the immediate needs of patients but also pave the way for future innovations.

Through a combination of pioneering research, strategic leadership, and a clear vision for the future, Corbus Pharmaceuticals is poised to create meaningful change in the biopharmaceutical landscape.

Frequently Asked Questions

What does Rachelle Jacques’ appointment as Board Chair signify for Corbus?

Her appointment represents a commitment to strong leadership and strategic direction as the company advances its innovative pipeline of treatments.

How long has Rachelle Jacques been with Corbus Pharmaceuticals?

Rachelle Jacques has been a member of the Corbus Pharmaceuticals Board for over six years before becoming Chair.

What are the primary goals of Corbus Pharmaceuticals?

Corbus aims to develop therapies that address serious health conditions, particularly in oncology and obesity, through innovative scientific approaches.

What role did Alan Holmer play in Corbus Pharmaceuticals?

Alan Holmer served as the founding Chair of the Board and has provided leadership over the past ten years, continuing to support the company as a Board member.

Where is Corbus Pharmaceuticals headquartered?

The company is headquartered in Norwood, Massachusetts, and focuses on developing advanced therapeutic solutions.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.